ALACT Stock Overview
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Acticor Biotech SAS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.27 |
| 52 Week High | €6.22 |
| 52 Week Low | €0.27 |
| Beta | -0.38 |
| 1 Month Change | -91.43% |
| 3 Month Change | -93.66% |
| 1 Year Change | -95.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALACT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -93.3% | -0.06% | -0.2% |
| 1Y | -95.0% | -4.3% | 2.4% |
Return vs Industry: ALACT underperformed the French Biotechs industry which returned -8.2% over the past year.
Return vs Market: ALACT underperformed the French Market which returned 4% over the past year.
Price Volatility
| ALACT volatility | |
|---|---|
| ALACT Average Weekly Movement | 28.2% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALACT's share price has been volatile over the past 3 months.
Volatility Over Time: ALACT's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 29 | Gilles Avenard | www.acticor-biotech.com |
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It’s product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19).
Acticor Biotech SAS Fundamentals Summary
| ALACT fundamental statistics | |
|---|---|
| Market cap | €3.55m |
| Earnings (TTM) | -€18.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs ALACT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALACT income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €18.65m |
| Earnings | -€18.65m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2,160.1% |
How did ALACT perform over the long term?
See historical performance and comparison